Latest News and Press Releases

-- Expect Q1 2024 product launch ---- Nitisinone market estimated to be more than $50 million annually ---- Eton will offer Eton Cares support program to all patients -- DEER PARK, Ill., Oct. 04,...

DEER PARK, Ill., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...

Total Q2 revenue of $12.0 million and net income of $4.6 millionProduct sales and royalty revenue of $6.5 million up 175% from Q2 2022 and 22% from Q1 2023$21.6 million of cash on handLaunched Betaine...

DEER PARK, Ill., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...

DEER PARK, Ill., June 28, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...

Product sales and royalty revenue of $5.3 million up 144% from Q1 2022 and 52% from Q4 2022Launched Betaine AnhydrousManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., May 11,...

-- Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* ---- Product is now available exclusively through Optime Care -- DEER PARK, Ill., May 10, 2023 ...

DEER PARK, Ill., May 03, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...

Q4 2022 revenue of $8.5 millionQ4 Product sales and royalty revenue up 220% from prior year and 9% from Q3Q4 positive net incomeManagement to hold conference call today at 4:30pm ET DEER PARK, Ill.,...

-- Product is targeting rare pediatric endocrinology condition ---- Potential for NDA submission in Q2 2024 -- DEER PARK, Ill., March 15, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or...